Pomalidomide experience: an effective therapeutic approach with immunomodulatory drugs in a patient with relapsed-refractory multiple myeloma.

No abstract is available for this paper.

• Publication year

  2017

• Venue

  Future Oncology

• Publication date

  2017-01-24

• Fields of study

  Medicine

• Identifiers
  DOI 10.2217/fon-2016-0368PMID 28116941
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Safety and efficacy of pomalidomide plus low-dose dexamethasone in STRATUS (MM-010): a phase 3b study in refractory multiple myeloma.

  2016cited by this paper
• Eribulin in 'field practice': an overview of the Italian experience.

  2015cited by this paper
• The European medicines agency review of pomalidomide in combination with low-dose dexamethasone for the treatment of adult patients with multiple myeloma: summary of the scientific assessment of the committee for medicinal products for human use.

  2015cited by this paper
• Impact of prior treatment and depth of response on survival in MM-003, a randomized phase 3 study comparing pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone in relapsed/refractory multiple myeloma

  2015cited by this paper
• In vivo murine model of acquired resistance in myeloma reveals differential mechanisms for lenalidomide and pomalidomide in combination with dexamethasone

  2014cited by this paper
• We need both randomized trials and real-world data: the example of everolimus as second-line therapy for mRCC.

  2014cited by this paper
• Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial.

  2013cited by this paper
• Pomalidomide: the new immunomodulatory agent for the treatment of multiple myeloma

  2013cited by this paper
• Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management

  2010cited by this paper
• Impact of optimal follow-up of monoclonal gammopathy of undetermined significance on early diagnosis and prevention of myeloma-related complications.

  2010cited by this paper
• International Myeloma Working Group molecular classification of multiple myeloma: spotlight review

  2009cited by this paper

• Lenalidomide and Pomalidomide Improve Function and Induce FcγRI/CD64 in Multiple Myeloma Neutrophils

  2021cites this paper
• Evidence-based recommendations for the management of symptoms and care for patients with multiple myeloma

  2020cites this paper
• Clinical Benefit of Long-Term Disease Control with Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma Patients

  2019cites this paper
• Renal, GI, and Peripheral Nerves: Evidence‐based recommendations for the management of symptoms and care for patients with multiple myeloma

  2017cites this paper
• Disease and Symptom Care: A Focus on Specific Needs of Patients With Multiple Myeloma
.

  2017cites this paper
• Overcoming the Straw Man Effect in Oncology: Visualization and Ranking of Chemotherapy Regimens Using an Information Theoretic Approach

  2017cites this paper